<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Lexicon Pharmaceuticals Inc — News on 6ix</title>
    <link>https://6ix.com/company/lexicon-pharmaceuticals-inc</link>
    <description>Latest news and press releases for Lexicon Pharmaceuticals Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 17 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/lexicon-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683594da78dffbe2df103e41.webp</url>
      <title>Lexicon Pharmaceuticals Inc</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc</link>
    </image>
    <item>
      <title>Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-to-present-data-at-the-american-academy-of-neurology-aan-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-to-present-data-at-the-american-academy-of-neurology-aan-annual-meeting</guid>
      <pubDate>Fri, 17 Apr 2026 12:00:00 GMT</pubDate>
      <description>Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further validates the broader potential importance of the AAK1 pathway in neurologic diseases THE WOODLANDS, Texas, April 17, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pai</description>
    </item>
    <item>
      <title>Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session &amp; Expo</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-announces-three-presentations-at-the-american-college-of-cardiology-acc-annual-scientific-session-and-expo</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-announces-three-presentations-at-the-american-college-of-cardiology-acc-annual-scientific-session-and-expo</guid>
      <pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
      <description>Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to</description>
    </item>
    <item>
      <title>Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-and-novo-nordisk-announce-initiation-of-phase-1-study-with-oral-obesity-drug-candidate-lx9851</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-and-novo-nordisk-announce-initiation-of-phase-1-study-with-oral-obesity-drug-candidate-lx9851</guid>
      <pubDate>Mon, 23 Mar 2026 11:30:00 GMT</pubDate>
      <description>LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential $10 million near-term milestone payments and is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales THE WOODLANDS, Texas, March 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and Novo Nordisk A/S t</description>
    </item>
    <item>
      <title>Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies &amp; Treatments for Diabetes</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-to-present-data-on-effect-of-kidney-function-on-the-long-term-efficacy-and-safety-of-sotagliflozin-in-patients-with-type-1-diabetes-at-19th-international-conference-on-advanced-technologies-and-treatments-for-diabetes</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-to-present-data-on-effect-of-kidney-function-on-the-long-term-efficacy-and-safety-of-sotagliflozin-in-patients-with-type-1-diabetes-at-19th-international-conference-on-advanced-technologies-and-treatments-for-diabetes</guid>
      <pubDate>Wed, 11 Mar 2026 12:00:00 GMT</pubDate>
      <description>Post hoc data analysis concluded that sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, improved glycemic control after one year in patients with normal and mildly reduced kidney functionTHE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin on people with type 1 diabetes will be delivered</description>
    </item>
    <item>
      <title>Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-reports-fourth-quarter-2025-financial-results-and-provides-clinical-updates-4</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-reports-fourth-quarter-2025-financial-results-and-provides-clinical-updates-4</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with</description>
    </item>
    <item>
      <title>Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-to-participate-in-three-upcoming-march-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-to-participate-in-three-upcoming-march-investor-conferences</guid>
      <pubDate>Tue, 03 Mar 2026 21:01:00 GMT</pubDate>
      <description>THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami on Wednesday, March 11, at 10:00 a.m. Lexicon will also be participating in 1x1 investor meetings at the 2026 Jefferies Biotech on the Beach Summit, March 10–11, and at the Barclays 28th Global Healthcare Conference, March 10-12. A live recordin</description>
    </item>
    <item>
      <title>Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-to-report-fourth-quarter-2025-financial-results-on-march-5-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-to-report-fourth-quarter-2025-financial-results-on-march-5-2026</guid>
      <pubDate>Thu, 26 Feb 2026 13:30:00 GMT</pubDate>
      <description>THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s web</description>
    </item>
    <item>
      <title>Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-announces-closing-approximately-94-221700283</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-announces-closing-approximately-94-221700283</guid>
      <pubDate>Fri, 06 Feb 2026 22:17:00 GMT</pubDate>
      <description>THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the closing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001, and concurrent private placement of 22,400,000 shares of common stock and 367,145 shares of series b convertible preferred stock (the “Series B Convertible Preferred Stock”). The shares of common stock offered pursuant to the public offering</description>
    </item>
    <item>
      <title>Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-announces-pricing-approximately-946-million-public-offering-and-concurrent</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-announces-pricing-approximately-946-million-public-offering-and-concurrent</guid>
      <pubDate>Fri, 30 Jan 2026 05:00:00 GMT</pubDate>
      <description>THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously</description>
    </item>
    <item>
      <title>Lexicon Announces Proposed Public Offering of Common Stock</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-announces-proposed-public-offering-213100985</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-announces-proposed-public-offering-213100985</guid>
      <pubDate>Thu, 29 Jan 2026 21:31:00 GMT</pubDate>
      <description>THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as</description>
    </item>
    <item>
      <title>Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-ring-nasdaq-closing-133000816</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-ring-nasdaq-closing-133000816</guid>
      <pubDate>Fri, 23 Jan 2026 13:30:00 GMT</pubDate>
      <description>THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026. The event will commemorate Lexicon’s 30th anniversary as a biopharmaceutical company building a differentiated pipeline of oral small-molecule therapies for people living with serious cardiometabolic diseases and chronic neuropathic pain. “In its early days, Lexicon was focused on pioneering a</description>
    </item>
    <item>
      <title>Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-announces-successful-end-133000106</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-announces-successful-end-133000106</guid>
      <pubDate>Wed, 21 Jan 2026 13:30:00 GMT</pubDate>
      <description>– No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo –THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) for pilavapadin in diabetic peripheral neuropathic pain (DPNP). During the meeting, the FDA raised no ob</description>
    </item>
    <item>
      <title>Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-provides-business-pipeline-123000131</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-provides-business-pipeline-123000131</guid>
      <pubDate>Mon, 12 Jan 2026 12:30:00 GMT</pubDate>
      <description>SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista on track for NDA resubmission and potential approval in 2026 Company presentation January 15 at 12:00 p.m. PT (3:00 p.m. ET) THE WOODLANDS, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a business and pipeline update at the 44th Annual J.P. Morgan Healthcare Co</description>
    </item>
    <item>
      <title>Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-publishes-relief-possible-133000809</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-publishes-relief-possible-133000809</guid>
      <pubDate>Fri, 09 Jan 2026 13:30:00 GMT</pubDate>
      <description>-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers to support millions of Americans suffering from chronic pain- THE WOODLANDS, Texas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- In October 2025, Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) convened an in-person Roundtable in Washington, D.C., to better understand the unmet needs of people living with chronic pai</description>
    </item>
    <item>
      <title>Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” </title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-publishes-relief-possible-ensuring-access-effective</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-publishes-relief-possible-ensuring-access-effective</guid>
      <pubDate>Fri, 09 Jan 2026 05:00:00 GMT</pubDate>
      <description>-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies-</description>
    </item>
    <item>
      <title>Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-present-44th-annual-133000139</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-present-44th-annual-133000139</guid>
      <pubDate>Wed, 07 Jan 2026 13:30:00 GMT</pubDate>
      <description>THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 12:00 p.m. PT (3:00 p.m. ET) in San Francisco. The live event and replay of the presentations can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with</description>
    </item>
    <item>
      <title>Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-announces-publication-preclinical-data-journal-endocrine</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-announces-publication-preclinical-data-journal-endocrine</guid>
      <pubDate>Wed, 10 Dec 2025 05:00:00 GMT</pubDate>
      <description>THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data</description>
    </item>
    <item>
      <title>Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/clinical-data-effect-sotagliflozin-adipose-distribution-non-diabetic-patients-will-be</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/clinical-data-effect-sotagliflozin-adipose-distribution-non-diabetic-patients-will-be</guid>
      <pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
      <description>THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in</description>
    </item>
    <item>
      <title>Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-participate-two-upcoming-december-investor-conferences-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-participate-two-upcoming-december-investor-conferences-2025</guid>
      <pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
      <description>THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate</description>
    </item>
    <item>
      <title>Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference</title>
      <link>https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-participate-jefferies-2025-london-healthcare-conference-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/lexicon-pharmaceuticals-inc/news/lexicon-pharmaceuticals-participate-jefferies-2025-london-healthcare-conference-2025</guid>
      <pubDate>Tue, 11 Nov 2025 05:00:00 GMT</pubDate>
      <description>THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate</description>
    </item>
  </channel>
</rss>